Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 11/20 | 0.67 |
| ▸ | HTR2A | P28223 | 2/20 | 0.67 |
| ▸ | HTR2C | P28335 | 2/20 | 0.67 |
| ▸ | HTR2B | P41595 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.67 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.67 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.67 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.67 |
| ▸ | HTR1A | P08908 | 1/20 | 0.67 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.67 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.67 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.67 |
| ▸ | DRD2 | P14416 | 1/20 | 0.67 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.67 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.67 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.67 |
| ▸ | DRD1 | P21728 | 1/20 | 0.67 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8878673 | 0.87 | HRH1 (0.65) | HRH1HTR2AHTR2CHTR2BMEN1 | |
| SCHEMBL6335568 | 0.84 | HRH1 (0.53) | HRH1HTR2AHTR2CHTR2BMEN1 | |
| Desloratadine SCHEMBL4425 | 0.81 | HRH1 (1.00) | HRH1HTR2AHTR2CHTR2BMEN1 | |
| Desloratadine SCHEMBL29390260 | 0.81 | HRH1 (1.00) | HRH1HTR2AHTR2CHTR2BMEN1 | |
| Desloratadine SCHEMBL29371361 | 0.81 | HRH1 (1.00) | HRH1HTR2AHTR2CHTR2BMEN1 | |
| SCHEMBL6178576 | 0.80 | HRH1 (0.73) | HRH1HTR2AHTR2CHTR2BMEN1 | |
| Desloratadine SCHEMBL4574215 | 0.80 | HRH1 (0.97) | HRH1HTR2AHTR2CHTR2BMEN1 | |
| Desloratadine SCHEMBL5198706 | 0.80 | HRH1 (0.97) | HRH1HTR2AHTR2CHTR2BMEN1 | |
| Desloratadine SCHEMBL5200429 | 0.80 | HRH1 (0.97) | HRH1HTR2AHTR2CHTR2BMEN1 | |
| Desloratadine SCHEMBL5200118 | 0.80 | HRH1 (0.97) | HRH1HTR2AHTR2CHTR2BMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1123931-B1 | Tricylic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases | SCHERING CORP (US) | 2005-06-01 | — | — | EP | disclosed |
| US-6492381-B1 | Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases | SCHERING CORP. | 2002-12-10 | — | — | US | disclosed |
| US-20020068742-A1 | Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases | BISHOP W ROBERT (US) | 2002-06-06 | — | — | US | disclosed |
| US-6365588-B1 | AS ANTINEOPLASTIC AGENT AND A POTENTIATING | SCHERING CORPORATION | 2002-04-02 | — | — | US | disclosed |
| EP-0723540-B1 | TRICYCLIC AMIDE AND UREA COMPOUNDS USEFUL FOR INHIBITION OF G-PROTEIN FUNCTION AND FOR TREATMENT OF PROLIFERATIVE DISEASES | SCHERING CORP (US) | 2001-12-12 | — | — | EP | disclosed |
| EP-0723538-B1 | TRICYCLIC CARBAMATE COMPOUNDS USEFUL FOR INHIBITION OF G-PROTEIN FUNCTION AND FOR TREATMENT OF PROLIFERATIVE DISEASES | SCHERING CORP (US) | 2001-12-12 | — | — | EP | disclosed |
| US-6300338-B1 | AS ANTITUMOR AGENT | SCHERING CORPORATION | 2001-10-09 | — | — | US | disclosed |
| EP-1123931-A1 | Tricylic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases | SCHERING CORPORATION (US) | 2001-08-16 | — | — | EP | disclosed |
| US-6242458-B1 | INHIBITING FARNESYL PROTEIN TRANSFERASE IN A HUMAN | SCHERING CORPORATION | 2001-06-05 | — | — | US | disclosed |
| US-6075025-A | Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases | SCHERING CORPORATION (US) | 2000-06-13 | — | — | US | disclosed |
| US-5977128-A | ENZYME INHIBITORS | SCHERING CORPORATION (US) | 1999-11-02 | — | — | US | disclosed |
| US-5665726-A | ANTIALLERGIC, ANTIINFLAMMATORY AGENTS | SCHERING CORPORATION (US) | 1997-09-09 | — | — | US | disclosed |
| EP-0535152-B1 | Bis-benzo or benzopyrido cyclo hepta piperidene, piperidylene and piperazine compounds as PAF antagonists and compositions thereof. | SCHERING CORP (US) | 1995-08-09 | — | — | EP | disclosed |
| US-5422351-A | Antiallergens; antiinflammatory agents | SCHERING CORPORATION (US) | 1995-06-06 | — | — | US | disclosed |
| EP-0396083-B1 | Heterocyclic N-oxide derivatives of substituted benzo[5,6]cycloheptapyridines, compositions and methods of use | SCHERING CORP (US) | 1994-11-30 | — | — | EP | disclosed |
| US-5151423-A | Antiinflammatory agents or antiallergens | SCHERING CORPORATION (US) | 1992-09-29 | — | — | US | disclosed |
| US-5089496-A | Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies | SCHERING CORPORATION (US) | 1992-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068742-A1 | Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases | RASGRP1, CCNA1, CCNA2 | HRH1 389/4885HTR2A 2768/4885HTR2C 2353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.